Bio-Thera Solutions has celebrated several firsts with the introduction of its Qletli (adalimumab) biosimilar in China. Not only does the product represent Bio-Thera’s first commercial launch, but it is also the first and only biosimilar rival to AbbVie’s Humira brand to have been approved by China’s National Medical Products Administration, Bio-Thera’s first biosimilar to receive approval, and only the second biosimilar to have been approved by the NMPA overall.
“The commercial launch of Bio-Thera’s first approved product is an enormous milestone for the company,” said CEO Shengfeng Li. “It...



